92 results
Page 2 of 5
8-K
r07rc9u3e7jmz 40fi82
24 Jan 24
Other Events
4:30pm
8-K
EX-99.1
m40i27720czboin7x
18 Jan 24
Other Events
9:08am
8-K
wmtfh3q6rloo9
17 Jan 24
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
6:05am
8-K
EX-99.1
6thyxxi7i
17 Jan 24
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
6:05am
8-K
EX-14.1
usi247eyfzv8q8tw
29 Nov 23
Entry into a Material Definitive Agreement
4:36pm
8-K
EX-3.2
g7qmy
29 Nov 23
Entry into a Material Definitive Agreement
4:36pm
6-K
EX-99.1
dq2 4lh6lvhkhpu5
26 Oct 23
Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
6:02am
6-K
EX-99.1
grc 3p5uv0
1 Sep 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
1piq7e6g
23 Aug 23
Report of Foreign Private Issuer
7:47pm
6-K
EX-99.1
v1sdfgh6aq irza0tf
22 Aug 23
Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
6:01am
6-K
EX-99.1
umo1f
27 Jul 23
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
8:47pm
6-K
EX-99.1
qxcrkx
25 Jul 23
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
9:42pm
6-K
EX-99.1
fo7b1 d3j
20 Jul 23
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
9:47pm
6-K
EX-99.1
e4zjy46863db 7b6b
18 Jul 23
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
6:04am
6-K
EX-99.1
btdi7qs0zh36q594
13 Jul 23
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
6:02am
6-K
EX-99.1
9gvlmcqmqh6g
5 Jul 23
Report of Foreign Private Issuer
8:47pm
6-K
EX-99.1
5mj0dp a8
15 Jun 23
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
9:06pm
6-K
EX-99.1
k38b28i8e0jfh1n 5q
30 May 23
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
i7emag6
18 May 23
Report of Foreign Private Issuer
8:00am